A novel compound bone articular repair material combining deproteinized osteoarticulation with calcium phosphate cement and BMP-9

Wu, Jun; Jiang, Linjun; Ju, Lingpeng; Zhang, Yuan; Li, Ming; Liu, Xing; Qu, Xiangyang

doi:10.1016/j.matdes.2021.110021

Cited by 2 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Synthetic materials also possess the advantageous possibility of incorporating components with anti-inflammation and antibiotic effects to reduce the possibility of complications [7] or biological factors, such as bone morphogenic proteins (BMP-9), to achieve an osteoinductive effect [8].…”

Section: Introductionmentioning

confidence: 99%

Biocompatibility Assessment of Two Commercial Bone Xenografts by In Vitro and In Vivo Methods

2022

View full text Add to dashboard Cite

Bone substitutes based on xenografts have been used for a long time in bone regeneration thanks to their inductive capacity for bone tissue regeneration. Some bone-based scaffolds have been modified by adding collagen and other proteins to improve their regenerative capacity and prevent migration and aggregation, especially particles. However, rejection of this graft has been reported due to protein residues caused by poor material preparation. We compared the in vitro and in vivo biological response of two commercial xenografts (InterOss®, F1 and InterOss® Collagen, F2) and a commercial porcine collagen membrane (InterCollagen® Guide, F3) as a rapid degradation control. Fourier Transform Infrared Spectroscopy (FT-IR) analysis evidenced the presence of hydroxyl, orthophosphate, and carbonate groups of the xenografts and amide groups of collagen. Thermogravimetric analysis (TGA) of the xenografts demonstrated their thermal stability and the presence of a few amounts of organic material. The study by differential scanning calorimetry showed the presence of endothermic peaks typical of the dehydration of the xenografts (F1 and F2) and for the collagen membrane (F3), the beginning of structural three-dimensional protein changes. Subsequently, in vitro biocompatibility tests were carried out for the materials with Artemia salina and MTT cell viability with HeLa cells, demonstrating the high biocompatibility of the materials. Finally, in vivo biocompatibility was studied by implanting xenografts in biomodels (Wistar rats) at different periods (30, 60, and 90 days). The F1 xenograft (InterOss) remained remarkably stable throughout the experiment (90 days). F2 (InterOss Collagen) presented a separation of its apatite and collagen components at 60 days and advanced resorption at 90 days of implantation. Finally, the collagen membrane (F3) presented faster resorption since, at 90 days, only some tiny fragments of the material were evident. All the in vivo and in vitro test results demonstrated the biocompatibility of the xenografts, demonstrating the potential of these materials for tissue engineering.

show abstract

Section: Introductionmentioning

confidence: 99%

Biocompatibility Assessment of Two Commercial Bone Xenografts by In Vitro and In Vivo Methods

2022

View full text Add to dashboard Cite

show abstract

In Vitro and In Vivo Evaluation of Injectable Strontium-Modified Calcium Phosphate Cement for Bone Defect Repair in Rats

Zhu

Tian

et al. 2022

IJMS

View full text Add to dashboard Cite

Calcium phosphate cement (CPC) has been widely studied, but its lack of osteoinductivity and inadequate mechanical properties limit its application, while strontium is able to promote bone formation and inhibit bone resorption. In this study, different proportions of tristrontium silicate were introduced to create a novel strontium-modified calcium phosphate cement (SMPC). The physicochemical properties of SMPC and CPC were compared, and the microstructures of the bone cements were characterized with scanning electron microscopy assays. Then, the effect of SMPC on cell proliferation and differentiation was examined. Furthermore, local inflammatory response and osteogenesis after SMPC implantation were also confirmed in the study. Finally, a rat model of isolated vertebral defects was used to test the biomechanical properties of the cements. The results showed that SMPC has better injectability and a shorter setting time than CPC. Meanwhile, the addition of tristrontium silicate promoted the mechanical strength of calcium phosphate cement, and the compressive strength of 5% SMPC increased to 6.00 ± 0.74 MPa. However, this promotion effect gradually diminished with an increase in tristrontium silicate, which was also found in the rat model of isolated vertebral defects. Furthermore, SMPC showed a more preferential role in promoting cell proliferation and differentiation compared to CPC. Neither SMPC nor CPC showed significant inflammatory responses in vivo. Histological staining suggested that SMPCs were significantly better than CPC in promoting new bone regeneration. Importantly, this osteogenesis effect of SMPC was positively correlated with the ratio of tristrontium silicate. In conclusion, 5% SMPC is a promising substitute material for bone repair with excellent physicochemical properties and biological activity.

show abstract

A novel compound bone articular repair material combining deproteinized osteoarticulation with calcium phosphate cement and BMP-9

Cited by 2 publications

References 28 publications

Biocompatibility Assessment of Two Commercial Bone Xenografts by In Vitro and In Vivo Methods

Biocompatibility Assessment of Two Commercial Bone Xenografts by In Vitro and In Vivo Methods

In Vitro and In Vivo Evaluation of Injectable Strontium-Modified Calcium Phosphate Cement for Bone Defect Repair in Rats

Contact Info

Product

Resources

About